Literature DB >> 9022771

Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients.

V Vilgrain1, B E Van Beers, J F Flejou, J Belghiti, M Delos, A L Gautier, M Zins, A Denys, Y Menu.   

Abstract

PURPOSE: Our goal was to determine the MR features of intrahepatic cholangiocarcinoma and to correlate them with pathologic findings in a surgical series.
METHOD: MRI in 14 patients with intrahepatic cholangiocarcinoma who had undergone resection was reviewed. All patients had T1- and T2-weighted SE sequences. Contrast-material-enhanced MRI was performed in 12 cases. Comparison between findings at MRI and pathologic examination was made.
RESULTS: MRI depicted all the lesions but one satellite nodule of 2 cm diameter. All lesions were hypointense relative to the liver on T1-weighted images. On T2-weighted images, the tumors were predominantly isointense or slightly hyperintense relative to liver parenchyma in nine cases (64%) and were strongly hyperintense in five cases (36%). Central hypointense areas or bands were seen in eight cases. No capsule was detected. On contrast-enhanced MR studies, all lesions had progressive and concentric filling with contrast material. Associated findings such as vascular encasement, focal liver atrophy, or dilatation of intrahepatic bile ducts were observed in 10 cases (71%). Comparison with pathologic examination revealed that lesion signal intensity on T2-weighted MR images was due mostly to the amount of fibrosis, necrosis, and mucous secretion within the lesion. The nine isointense or slightly hyperintense lesions contained abundant fibrosis and had a low content of mucous secretion or necrosis, whereas the five hyperintense lesions contained low or moderate fibrosis and prominent mucous secretion and/or necrosis.
CONCLUSION: Our study suggests that the MR features of intrahepatic cholangiocarcinoma are well correlated with pathologic findings, but are nonspecific. Associated findings may strengthen the diagnosis of intrahepatic cholangiocarcinoma at MRI.

Entities:  

Mesh:

Year:  1997        PMID: 9022771     DOI: 10.1097/00004728-199701000-00012

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  9 in total

Review 1.  Imaging of Cholangiocarcinoma.

Authors:  Susann-Cathrin Olthof; Ahmed Othman; Stephan Clasen; Christina Schraml; Konstantin Nikolaou; Malte Bongers
Journal:  Visc Med       Date:  2016-12-06

Review 2.  Multimodality imaging of intrahepatic cholangiocarcinoma.

Authors:  Kelly Fábrega-Foster; Mounes Aliyari Ghasabeh; Timothy M Pawlik; Ihab R Kamel
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 3.  Clinical diagnosis and staging of cholangiocarcinoma.

Authors:  Boris Blechacz; Mina Komuta; Tania Roskams; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-02       Impact factor: 46.802

4.  Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions.

Authors:  Kenneth Coenegrachts
Journal:  World J Radiol       Date:  2009-12-31

5.  Staging cholangiocarcinoma by imaging studies.

Authors:  V Vilgrain
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

6.  Diagnosis of cholangiocarcinoma.

Authors:  B E Van Beers
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

7.  Magnetic Resonance Imaging of cholangiocarcinoma.

Authors:  Katrina A Vanderveen; Hero K Hussain
Journal:  Cancer Imaging       Date:  2004-04-06       Impact factor: 3.909

8.  Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine.

Authors:  Luigi Grazioli; Maria Pia Bondioni; Niccolò Faccioli; Sebastiana Gambarini; Rita Tinti; Günther Schneider; Miles Kirchin
Journal:  J Gastrointest Cancer       Date:  2010-12

Review 9.  Hepatic capsular retraction: spectrum of diagnosis at MRI.

Authors:  David Da Ines; Antoine Mons; Chadi Braidy; Pierre François Montoriol; Jean-Marc Garcier; Valérie Vilgrain
Journal:  Acta Radiol Short Rep       Date:  2014-12-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.